Patents by Inventor Robert Mansfield

Robert Mansfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230147756
    Abstract: Described herein is the farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
    Type: Application
    Filed: March 17, 2021
    Publication date: May 11, 2023
    Inventors: Nicholas D. SMITH, Robert MANSFIELD
  • Publication number: 20230120914
    Abstract: Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Application
    Filed: March 17, 2021
    Publication date: April 20, 2023
    Inventors: Nicholas D. SMITH, Robert MANSFIELD
  • Publication number: 20220235063
    Abstract: The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease.
    Type: Application
    Filed: August 27, 2021
    Publication date: July 28, 2022
    Inventor: Robert MANSFIELD
  • Publication number: 20210347736
    Abstract: Described herein is the farnesoid X receptor agonist, trans-N-(3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-N-((trans-4-(4-methoxy-3-methyl phenyl)cyclohexyl)methyl)cyclohexane-carboxamide, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.
    Type: Application
    Filed: September 17, 2019
    Publication date: November 11, 2021
    Inventors: Nicholas D. SMITH, Robert MANSFIELD
  • Patent number: 11136332
    Abstract: The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: October 5, 2021
    Assignee: Celgene International II Sàrl
    Inventor: Robert Mansfield
  • Publication number: 20210017185
    Abstract: The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease.
    Type: Application
    Filed: May 28, 2020
    Publication date: January 21, 2021
    Inventor: Robert MANSFIELD
  • Patent number: 10703760
    Abstract: The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: July 7, 2020
    Assignee: Celgene International II Sàrl
    Inventor: Robert Mansfield
  • Publication number: 20190185482
    Abstract: The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 20, 2019
    Inventor: Robert MANSFIELD
  • Publication number: 20150169131
    Abstract: A motion sensitive input control configured to prevent unintended input caused by inadvertent movement of a computing device. In one embodiment, unintended input can be prevented by disregarding an input event if a change in motion of the computing device is detected simultaneously with or immediately prior to the detected input event. In another embodiment, unintended input can be prevented by reducing the sensitivity of an input device during a motion-based state associated with the computing device. In this manner, the likelihood of inadvertent motion of a computing device causing an unintended input event can be reduced.
    Type: Application
    Filed: March 2, 2015
    Publication date: June 18, 2015
    Inventors: Myra Mary HAGGERTY, Robert Mansfield
  • Patent number: 8970475
    Abstract: A motion sensitive input control configured to prevent unintended input caused by inadvertent movement of a computing device. In one embodiment, unintended input can be prevented by disregarding an input event if a change in motion of the computing device is detected simultaneously with or immediately prior to the detected input event. In another embodiment, unintended input can be prevented by reducing the sensitivity of an input device during a motion-based state associated with the computing device. In this manner, the likelihood of inadvertent motion of a computing device causing an unintended input event can be reduced.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: March 3, 2015
    Assignee: Apple Inc.
    Inventors: Myra Mary Haggerty, Robert Mansfield
  • Publication number: 20100321286
    Abstract: A motion sensitive input control configured to prevent unintended input caused by inadvertent movement of a computing device. In one embodiment, unintended input can be prevented by disregarding an input event if a change in motion of the computing device is detected simultaneously with or immediately prior to the detected input event. In another embodiment, unintended input can be prevented by reducing the sensitivity of an input device during a motion-based state associated with the computing device. In this manner, the likelihood of inadvertent motion of a computing device causing an unintended input event can be reduced.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 23, 2010
    Inventors: Myra Mary Haggerty, Robert Mansfield
  • Publication number: 20080143836
    Abstract: A video surveillance camera is provided that includes a first camera objective directed towards a primary surveillance field of view and at least a second camera objective that is concealed within the camera and directed towards a second covert field of view. The second camera objective is mounted within the camera body in a manner that makes it undetectable, while allowing the camera objective to freely observe the covert field of view. In a first embodiment, the video camera includes a first camera objective affixed to the front of the camera housing and at least a second camera objective mounted in a fixed, concealed position within the housing. Alternately, the at least one second camera objective may be mounted within the housing in an adjustable fashion to allow the second camera objective to be aimed independently of the camera housing orientation itself.
    Type: Application
    Filed: July 13, 2007
    Publication date: June 19, 2008
    Applicant: VIDEOLOGY IMAGING SOLUTIONS, INC.
    Inventors: Richard Nowicki, Robert Mansfield
  • Publication number: 20080095507
    Abstract: The invention relates to high-strength, abrasion-resistant optical fiber cable having a supplemental layer consisting essentially of a liquid crystal polymer (LCP) to enhance the cable's tensile strength and hermetically seal it, and an outermost encasing layer to protect the LCP supplemental layer from damage that could otherwise diminish the tensile strength or destroy the moisture barrier properties of the cable gained by adding the supplemental liquid crystal polymer layer. The encasing layer is preferably a thin layer of a smooth, non-crystalline thermoplastic that can be easily removed with chemicals that do not affect the properties of the supplemental layer so that the supplemental layer can be made accessible for promoting the formation of hermetically sealed interfaces between the cable and other structures. Cross-head extrusion methods for coating optical fibers with LCP and encasing layers are described along with laser and ultrasonic bonding techniques for fabricating hermetic packages.
    Type: Application
    Filed: November 27, 2007
    Publication date: April 24, 2008
    Inventors: Amaresh Mahapatra, Robert Mansfield
  • Patent number: 7355043
    Abstract: A process for the preparation of a compound of formula (A) wherein: X is hydrogen or hydroxy, chloro, C1-6 alkoxy or pheny C1-6 alkoxy; and Ra and Rb are hydrogen, or acyl or phosphate derivatives thereof, which process comprises: (i) the preparation of a compound of formula (I) wherein R1 is C1-6 alkyl, or phenyl C1-6 alkyl in which the phenyl group is optionally substituted; R2 is hydrogen, hydroxy, chlorine, C1-6 alkoxy, phenyl C1-6 alkoxy or amino; and R3 is halogen, C1-6 alkylthio, C1-6 alkylsulphonyl, azido, an amino group or a protected amino group, which preparation comprises the reaction of a compound of formula (II) wherein R2 and R3 are as defined for formula (I) with a compound of formula (V) wherein L is a leaving group and R1 is as defined for formula (I), to give a compound of formula (VI), and thereafter converting the intermediate compound of formula (VI) to a compound of formula (I) via decarboxylation, and as necessary or desired, interconverting variables R1, R2 and R3 to further values of
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: April 8, 2008
    Assignee: Novartis International Pharmaceutical Ltd.
    Inventor: John Robert Mansfield Dales
  • Publication number: 20070129342
    Abstract: Provided are pharmaceutical compositions containing an oil phase and an aqueous phase, the oil phase including an ansamycin and less than 2% w/w oleic acid, wherein the ansamycin is geldanamycin, 17-aminogeldanamycin, 17-allyalamino-17-demethoxy-geldanamycin, compound 563, or compound 237 having the structures below, or a salt of any one of the aforementioned ansamycins
    Type: Application
    Filed: November 30, 2006
    Publication date: June 7, 2007
    Applicant: CONFORMA THERAPEUTICS CORPORATION
    Inventors: Robert Mansfield, Edgar Ulm
  • Publication number: 20060228405
    Abstract: Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid of medium and long chain triglycerides.
    Type: Application
    Filed: April 7, 2006
    Publication date: October 12, 2006
    Inventors: Edgar Ulm, Robert Mansfield, Gregg Timony, Marcus Boehm
  • Publication number: 20060148776
    Abstract: Drug formulations having emulsifying agents and both medium and long chain triglycerides are described. In preferred embodiments, the long chain triglycerides negate or lessen deleterious central nervous system effects that are caused by medium chain triglycerides.
    Type: Application
    Filed: October 4, 2003
    Publication date: July 6, 2006
    Applicant: Conforma Therapeutics Corporation
    Inventors: Edqar Ulm, Robert Mansfield, Marcus Boehm
  • Publication number: 20060067953
    Abstract: Oral pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, In preferred embodiments, the pharmaceutically active compounds are ansamycins, pharmaceutically acceptable salts, or prodrugs thereof.
    Type: Application
    Filed: September 29, 2004
    Publication date: March 30, 2006
    Inventors: Robert Mansfield, Edgar Ulm, Gregg Timony
  • Publication number: 20050154751
    Abstract: A system comprises business logic operable for managing and administering company entities, records, documents, equity instruments, and stakeholders, a database storing data associated with the business logic, integration logic operable to integrate the business logic and its associated data with existing enterprise systems and data associated therewith, and a graphical user interface presenting a hierarchical tree view of the company entities, records, documents, equity instruments, and stakeholders.
    Type: Application
    Filed: November 3, 2004
    Publication date: July 14, 2005
    Applicant: Boardroom Software, Inc.
    Inventors: Andrew Levi, Bradley Bauer, Robert Woldberg, Robert Mansfield
  • Patent number: D793494
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: August 1, 2017
    Inventors: Robert Mansfield, John Ou Yang, Even Li, Town Wen, Ivan Qin, Robin Xue, Ryan Cai